davunetide and Cognitive-Dysfunction

davunetide has been researched along with Cognitive-Dysfunction* in 1 studies

Trials

1 trial(s) available for davunetide and Cognitive-Dysfunction

ArticleYear
A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment.
    Dementia and geriatric cognitive disorders, 2013, Volume: 35, Issue:5-6

    AL-108-211 was a placebo-controlled, ascending-dose study that explored the safety, tolerability and efficacy of 12 weeks of treatment with AL-108 in subjects with amnestic mild cognitive impairment.. A total of 144 subjects were randomized in a 2:1 drug:placebo ratio. Subjects were enrolled into the low-dose group or placebo and then to the high-dose group or placebo. Pooling of the placebo groups yielded 3 groups (approx. 48/group) whose baseline demographics and disease characteristics were well matched.. AL-108 was generally safe and well tolerated. Analyses of efficacy data failed to detect a statistically significant difference between the treatment groups on the composite cognitive memory score. Analyses of the individual cognitive tasks identified signals of potential efficacy in 2 tests of memory and attention.. These data suggest that AL-108 was generally safe, well tolerated and merits additional investigation as a treatment for Alzheimer's disease.

    Topics: Administration, Intranasal; Aged; Aged, 80 and over; Cognition; Cognitive Dysfunction; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Oligopeptides; Paired-Associate Learning; Patient Compliance; Space Perception

2013